ESTEVE and KOWA Pharmaceuticals America enter into an Exclusive License and Commercialization Agreement for rights to E-58425 for the potential management of acute pain(1-9) in the United States(8,9)
ESTEVE and KOWA Pharmaceuticals America enter into an Exclusive License and Commercialization Agreement for rights to E-58425 for the potential management of acute pain(1-9) in the United States(8,9) celecoxib and tramadol (8,9) BARCELONA, Spain, May 3, 2021 /PRNewswire/ -- Esteve Pharmaceuticals (ESTEVE), an international specialty pharmaceutical company devoted to the development and commercialization of innovative products, today announced an agreement with Kowa Pharmaceuticals America, Inc. (KPA) under which ESTEVE has granted KPA exclusive rights to commercialize E-58425 in the United St...
Source: finanznachrichten.de
![ESTEVE and KOWA Pharmaceuticals America enter into an Exclusive [...] | Comunicati stampa CataniaOggi - Vimarsana News](https://www.cataniaoggi.it/img/logo_social.jpg){kind=logo}